Products for Research Use Only

Anamorelin

CAT: 0804-HY-14734-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14734-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia[1][2].
CAS Number
249921-19-5
Product Name Alternative
RC-1291; ONO-7643
UNSPSC
12352005
Hazard Statement
H301
Target
GHSR
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Anamorelin.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
[H][C@](CC1=CNC2=CC=CC=C21)(NC(C(C)(C)N)=O)C(N3CCC[C@@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)C3)=O
Molecular Formula
C31H42N6O3
Molecular Weight
546.70
Precautions
H301
References & Citations
[1]Pietra C, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexiasyndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5 (4) :329-37.|[2]Northrup R, et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer. 2013 Sep;21 (9) :2409-15.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Discov Med. 2024 Sep 17.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Pharm Biomed Anal. 2016 Nov 30:131:482-496.|J Sep Sci. 2016 Jan;39 (2) :333-41.|Mass Spectrom Lett. 2016 Sep 30;7 (3) :55-63.|Mass Spectrom Lett. 2016, 7 (3) :55-63.|Universität Zürich. 2023 Jun 14.|Patent. US20240139176A1.|Patent. US20240197718A1.